Ambrx Biopharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Ambrx Biopharma's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 41% per year.
Belangrijke informatie
-29.9%
Groei van de winst
-2.2%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -41.0% |
| Rendement op eigen vermogen | -27.7% |
| Nettomarge | -1,638.3% |
| Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Ambrx Biopharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 23 | 4 | -67 | 31 | 36 |
| 30 Jun 23 | 6 | -60 | 26 | 32 |
| 31 Mar 23 | 6 | -71 | 25 | 36 |
| 31 Dec 22 | 7 | -78 | 23 | 41 |
| 30 Sep 22 | 6 | -87 | 21 | 59 |
| 30 Jun 22 | 5 | -91 | 20 | 63 |
| 31 Mar 22 | 7 | -76 | 19 | 56 |
| 31 Dec 21 | 7 | -68 | 18 | 53 |
| 30 Sep 21 | 10 | -54 | 16 | 42 |
| 30 Jun 21 | 12 | -40 | 13 | 31 |
| 31 Mar 21 | 13 | -28 | 10 | 25 |
| 31 Dec 20 | 14 | -17 | 8 | 19 |
| 31 Dec 19 | 10 | -20 | 8 | 25 |
Kwaliteitswinsten: AMAM is currently unprofitable.
Groeiende winstmarge: AMAM is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AMAM is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Versnelling van de groei: Unable to compare AMAM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AMAM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Rendement op eigen vermogen
Hoge ROE: AMAM has a negative Return on Equity (-27.66%), as it is currently unprofitable.